📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
128 announcements match the current filters (relevance ≥ 5).
Mankind Pharma to Divest Non-Core Unit for ₹49 Cr; Sets Up Netherlands R&D Hub
Mankind Pharma has approved the 100% divestment of Broadway Hospitality Services for ₹49 crore to AKRK Projects LLP, exiting a non-core asset that contributed just 0.07% to its total turnover. Simultaneously, the company is incorporating a wholly-owned subsidiary in the Netherlands with an initial investment of up to Euro 5 million. This new entity will act as a Special Purpose Vehicle (SPV) for R&D assets and business development in niche therapies. These moves reflect a strategic shift toward streamlining operations and focusing on high-value specialty pharmaceutical segments.
Confidence: HIGH
What changedMankind is exiting the hospitality business and establishing an international corporate structure for R&D and strategic investments.
Why it mattersThe divestment removes a non-core distraction, while the Netherlands SPV provides a platform for global R&D collaborations and potential technology acquisitions in high-barrier segments.
Divestment Consideration: ₹49.00 CrBroadway Revenue Contribution: 0.07%Broadway Net Worth: ₹38.99 CrProposed Netherlands Investment: Up to Euro 5 MillionDivestment vs TTM Revenue: ~0.34%
📅 Short termMinimal impact expected on the stock price due to the small scale of the transaction relative to the company's ₹1.07 lakh crore market cap.
📈 Long termStructurally positive as it demonstrates capital discipline by exiting non-core assets and building a dedicated vehicle for international R&D expansion.
⚠ Risk flags
- Execution risk in international R&D ventures
- Regulatory approvals for overseas investment
Key Highlights
Divestment of Broadway Hospitality for ₹49 crore, representing a premium over its ₹38.99 crore net worth.
Broadway Hospitality contributed only ₹9.63 crore (0.07%) to Mankind's TTM revenue.
New Netherlands subsidiary to be funded with up to Euro 5 million for R&D and niche therapy investments.
Divestment transaction is expected to be completed within a 90-day timeline.
The buyer, AKRK Projects LLP, is a third party and not part of the promoter group.
👀 What to Watch
Investors should watch for future announcements regarding the specific 'niche therapies' or R&D assets the Netherlands SPV acquires, as this will signal the company's next growth phase beyond the BSV integration.
18.6% Advance Growth: Bank of India Reports Strong Q1 FY27 Provisional Business Figures
Bank of India reported a robust 16.58% YoY growth in total global business, reaching ₹17,55,915 crore as of June 30, 2026. Global gross advances grew by 18.64% YoY to ₹7,97,798 crore, significantly exceeding the bank's previous guidance of 12-13%. The high-yield Domestic RAM (Retail, Agri, MSME) segment showed strong momentum with a 19.69% YoY increase, while global deposits grew by 14.92% YoY to ₹9,58,117 crore.
Confidence: HIGH
What changedThe bank has released its provisional business updates for Q1 FY27, showing credit growth that significantly outpaces its earlier annual guidance of 12-13%.
Why it mattersStrong credit growth, particularly in the RAM segment, suggests the bank is successfully executing its high-yield strategy, which could lead to improved profitability if asset quality remains stable.
Global Gross Advances: ₹7,97,798 crGlobal Deposits: ₹9,58,117 crYoY Advance Growth: 18.64%Domestic RAM Advance Growth: 19.69%Total Business vs Market Cap: ~27.2x
📅 Short termThe stock may see positive sentiment in the short term as the credit growth figures are ahead of historical targets and industry averages.
📈 Long termIf the bank can maintain this growth trajectory while managing credit costs, it may lead to a valuation re-rating from its current P/B of 0.7.
⚠ Risk flags
- Potential pressure on Net Interest Margins (NIM) if deposit costs rise
- Asset quality risks in the rapidly expanding RAM segment
- Macroeconomic sensitivity of the international portfolio (15.76% of advances)
Key Highlights
Global Gross Advances increased 18.64% YoY to ₹7,97,798 crore as of June 30, 2026
Domestic RAM advances grew 19.69% YoY to ₹3,92,647 crore, supporting the high-yield strategy
Total Global Business reached ₹17,55,915 crore, representing a 16.58% YoY growth
Global Deposits rose 14.92% YoY to ₹9,58,117 crore compared to ₹8,33,698 crore in the previous year
Domestic Advances grew 19.12% YoY, outperforming the overall global growth rate
👀 What to Watch
Investors should monitor the upcoming full Q1 FY27 results to evaluate if this aggressive credit growth has impacted Net Interest Margins (NIMs) or asset quality. Key focus should be on the CASA ratio to assess the sustainability of deposit costs.
Bank of India Approves ₹4.65 Dividend and Appoints New Executive Director at 30th AGM
Bank of India held its 30th Annual General Meeting on June 15, 2026, where shareholders approved the audited financial statements for the year ended March 31, 2026. A dividend of ₹4.65 per equity share (46.50%) was declared for the fiscal year 2025-26. The appointment of Shri Pramod Kumar Dwibedi as Executive Director was officially approved by the shareholders. The Government of India, holding a 73.38% stake, was represented at the meeting, and all resolutions were passed with the requisite majority.
Key Highlights
Approved a dividend of ₹4.65 per equity share (46.50%) for the financial year 2025-26.
Confirmed the appointment of Shri Pramod Kumar Dwibedi as the Executive Director of the Bank.
Adopted the Audited Balance Sheet and Profit and Loss Account for the year ended March 31, 2026.
The Government of India remains the majority shareholder with a 73.38% stake in the bank.
👀 What to Watch
Investors should note the dividend payout of ₹4.65 per share and the formalization of the new Executive Director's role, which ensures management continuity.
Bank of India Approves ₹4.65 Dividend per Share at 30th AGM; Appoints New Executive Director
Bank of India held its 30th Annual General Meeting on June 15, 2026, where shareholders approved all key resolutions including the financial results for FY 2025-26. A significant outcome for investors is the declaration of a dividend at ₹4.65 per equity share (46.50%). The bank also confirmed the appointment of Shri Pramod Kumar Dwibedi as Executive Director. The Government of India, as the majority shareholder, maintains a 73.38% stake in the bank.
Key Highlights
Approved a dividend of ₹4.65 per equity share (46.50%) for the financial year 2025-26.
Adopted the Audited Balance Sheet and Profit and Loss Account for the year ended March 31, 2026.
Confirmed the appointment of Shri Pramod Kumar Dwibedi as the Executive Director of the Bank.
The Government of India remains the dominant shareholder with a 73.38% stake.
All resolutions were passed with the requisite majority via remote e-voting and meeting-day voting.
👀 What to Watch
Investors should track the record date for the ₹4.65 dividend payout. The bank's stability is supported by high government ownership and the formalization of its leadership team.
JNK India Secures Large Export Order Worth ₹100-300 Cr for ADNOC Project in UAE
JNK India Limited has bagged a 'Large' export order from CC7 Emirates Engineering Solutions L.L.C., UAE, for the TA’ZIZ Salt Project under ADNOC, Abu Dhabi. The order is valued between ₹100 Crores and ₹300 Crores and involves the design, engineering, and supply of an Incinerator Package for waste gas handling. This contract marks a significant start to FY27, showcasing the company's international competitiveness in specialized engineered equipment. The scope includes manufacturing and procurement on an FCA basis along with commissioning assistance.
Key Highlights
Order value is classified in the 'Large' category, ranging from ₹100 Crores to ₹300 Crores.
The contract is for the TA’ZIZ Salt Project for ADNOC in Abu Dhabi, UAE.
Scope includes design, engineering, manufacture, and supply of an Incinerator Package for waste gas handling.
This represents a major export win at the beginning of FY27, strengthening the company's global footprint.
The project will be executed on an FCA (Free Carrier) basis with additional per diem assistance for commissioning.
👀 What to Watch
Investors should monitor the company's order book growth and execution efficiency, as this export win validates JNK India's technical capabilities in the high-margin international market.
JNK India Bags "Large" Order Worth ₹100-300 Cr for ADNOC Project in UAE
JNK India Limited has secured a significant international order from CC7 Emirates Engineering Solutions L.L.C. for the TA’ZIZ Salt Project in Abu Dhabi, UAE. The order is classified as "Large," which according to the company's internal classification, ranges between ₹100 crore and ₹300 crore. The contract involves the design, engineering, and supply of an Incinerator Package, with a project delivery schedule set for December 2027. This win strengthens JNK India's presence in the Middle East and provides healthy revenue visibility for the coming years.
Key Highlights
Order value classified as 'Large', ranging between ₹100 crore and ₹300 crore.
International contract for ADNOC's TA’ZIZ Salt Project in Abu Dhabi, UAE.
Scope includes design, engineering, manufacture, and supply of an Incinerator Package.
Project execution timeline is set for completion by December 2027.
Contract includes per diem assistance for erection, commissioning, and performance tests.
👀 What to Watch
Investors should view this as a positive development that bolsters the order book and demonstrates technical competency in international markets. Monitor the company's execution capabilities and margin profile for such high-value engineering projects.
NK Industries Reports FY26 Net Loss of ₹2.77 Crore; Net Worth Remains Deeply Negative
NK Industries reported a standalone net loss of ₹277.35 lakhs for the fiscal year ended March 31, 2026, compared to a loss of ₹314.63 lakhs in the previous year. Annual revenue remained stagnant at ₹240 lakhs, while the company continues to struggle with a massive negative net worth of over ₹513 crore. The auditors have issued a modified opinion due to ongoing legal disputes involving the NSEL scam, asset attachments under the MPID Act, and PMLA investigations. The company's financial health remains critical with significant legal and regulatory overhangs.
Key Highlights
Standalone annual revenue for FY26 remained flat at ₹240.00 lakhs compared to the previous year.
Net loss for the full year narrowed slightly to ₹277.35 lakhs from ₹314.63 lakhs in FY25.
The company's Other Equity is deeply negative at ₹51,377.79 lakhs, indicating total erosion of net worth.
Auditors issued a modified opinion citing pending litigations and attachment of plant and machinery by the Government of Maharashtra.
Q4 FY26 revenue saw a 32% year-on-year decline to ₹60.00 lakhs from ₹88.28 lakhs in Q4 FY25.
👀 What to Watch
Investors should avoid this stock due to the complete erosion of net worth and severe legal risks associated with the NSEL scam and PMLA proceedings. The company's ability to continue as a going concern is under significant pressure given the attachment of its primary assets.
JNK India FY26 PAT Surges 115% to ₹64.8 Cr; Order Book Reaches ₹1,961 Cr
JNK India reported a stellar performance for FY26, with total revenue growing 68% YoY to ₹838 crores and PAT doubling to ₹64.8 crores. The company's order book reached a robust ₹1,961.4 crores, providing strong revenue visibility for the next two years. Management has guided for a 25-30% revenue growth in FY27, supported by a healthy pipeline of domestic and international projects, including opportunities in Africa and the Middle East. The newly formed joint venture in clean energy already contributed 7% to the group revenue within its first six months of operation.
Key Highlights
FY26 Revenue increased by 68% YoY to ₹838 crores, while Q4 FY26 revenue grew 69.2% to ₹344.6 crores
Full-year PAT rose 114.6% YoY to ₹64.8 crores, with Q4 PAT jumping 149.5% to ₹33 crores
Order book as of March 31, 2026, stands at ₹1,961.4 crores, with FY26 inflows of ₹1,694.4 crores
EBITDA margins improved to 15.2% in Q4 FY26, driven by a better project mix and completion of legacy orders
Management expects 25-30% revenue growth in FY27 and is bidding for export opportunities worth ₹4,000 crores
👀 What to Watch
Investors should view the strong order book and margin expansion as positive indicators of execution capability. Monitor the conversion of the ₹4,000 crore export pipeline and progress in the green hydrogen JV for long-term growth.
Mankind Pharma Q4 FY26 Revenue Up 11.8% to INR 3,443 Cr; Q4 PAT Jumps 30.4%
Mankind Pharma reported a strong performance for Q4 FY26 with revenue growing 11.8% YoY to INR 3,443 crores and PAT increasing 30.4% to INR 559 crores. For the full year FY26, revenue reached INR 14,278 crores, a 17% increase, driven by robust domestic growth and a 35% surge in international business. The company successfully increased its chronic therapy share to 40% and saw volume growth improve to 2.3% from 0.5% in the previous year. While annual PAT dipped slightly by 3.4% due to finance and depreciation costs from the BSV acquisition, adjusted EBITDA margins remained healthy at 25.4%.
Key Highlights
Q4 FY26 revenue grew 11.8% YoY to INR 3,443 crores with adjusted EBITDA margins expanding to 27.1%.
Chronic therapy contribution increased to 40% in Q4, with cardiac and anti-diabetic segments outperforming the market.
Full-year FY26 volume growth improved significantly to 2.3% compared to 0.5% in FY25.
International business revenue surged 35% YoY to INR 2,061 crores for the full year FY26.
Acquired the 'Rivotril' brand from Roche to strengthen the specialty chronic portfolio in neurology and psychiatry.
👀 What to Watch
Investors should take note of the significant margin expansion and the strategic shift toward high-margin chronic therapies. The recovery in volume growth and successful integration of the BSV portfolio position the company well for sustainable long-term growth.
Bank of India to Hold 30th AGM on June 15, 2026; Proposes ₹4.65 Dividend per Share
Bank of India has scheduled its 30th Annual General Meeting (AGM) for June 15, 2026, to be conducted via video conferencing. A key agenda item is the declaration of a dividend of ₹4.65 per equity share (46.50%) for the financial year 2025-26. The bank has fixed May 29, 2026, as the record date for determining dividend eligibility. Shareholders will also vote on the appointment of Shri Pramod Kumar Dwibedi as Executive Director and the adoption of audited financial statements for the year ended March 31, 2026.
Key Highlights
Proposed dividend of ₹4.65 per equity share (46.50%) for the financial year 2025-26.
Record date for dividend eligibility is set for May 29, 2026.
30th AGM scheduled for June 15, 2026, at 11:00 AM via Video Conferencing.
Appointment of Shri Pramod Kumar Dwibedi as Executive Director with a term until June 30, 2028.
Remote e-voting facility available from June 12 to June 14, 2026.
👀 What to Watch
Investors interested in the dividend should ensure they hold the stock prior to the record date of May 29, 2026. Shareholders should also review the annual report and participate in the e-voting process regarding management appointments.
JNK India FY26 PAT Surges 115% to ₹65 Cr; Order Book Reaches Record ₹1,961 Cr
JNK India reported a stellar performance for FY26, with annual revenue growing 68% YoY to ₹838 crore and Profit After Tax (PAT) more than doubling to ₹64.8 crore. The company's order book saw significant growth, ending the year at ₹1,961 crore, providing strong revenue visibility for the coming years. Profitability margins improved across the board, with the Q4 PAT margin expanding by 309 basis points to 9.6%. Additionally, the company's strategic foray into green hydrogen via its new JV, JNK Chemdist, has already started contributing 7% to the group revenue.
Key Highlights
FY26 Revenue increased by 68% YoY to ₹838 crore, while PAT surged 114.6% to ₹64.8 crore.
Order book grew 1.8x to ₹1,961 crore as of March 31, 2026, with annual order inflows of ₹1,694 crore.
Q4 FY26 EBITDA margins expanded by 165 bps YoY to 15.2% with a quarterly PAT of ₹33 crore.
Return on Equity (ROE) improved significantly to 12.1% from 8.6% in the previous fiscal year.
New JV JNK Chemdist Technologies contributed approximately 7% to the total group revenue in its first year of operations.
👀 What to Watch
Investors should view the strong order book and margin expansion as positive indicators of execution capability and scalability. The company's successful entry into the green hydrogen space makes it a key beneficiary of the clean energy transition.
JNK India FY26 PAT Surges 114.6% to ₹64.8 Cr; Order Book Reaches ₹1,961.4 Cr
JNK India reported a stellar performance for FY26, with total revenue growing 68% YoY to ₹838.0 Cr and Profit After Tax (PAT) more than doubling to ₹64.8 Cr. The company's order book stands at a robust ₹1,961.4 Cr, driven by significant inflows of ₹1,694.4 Cr during the year, including critical green hydrogen and cracking furnace projects. Operational efficiency improved significantly, with EBITDA margins expanding to 13.3% and ROCE rising to 19.1%. The board has also recommended a 15% final dividend, reflecting confidence in the company's growth trajectory and cash flow.
Key Highlights
FY26 Revenue increased by 68.0% YoY to ₹838.0 Cr, while Q4 revenue grew 69.2% YoY to ₹344.6 Cr.
Full-year PAT surged 114.6% YoY to ₹64.8 Cr with PAT margins expanding by 163 bps to 7.7%.
Strong order book of ₹1,961.4 Cr as of March 31, 2026, supported by ₹1,694.4 Cr in new order inflows during the year.
Return on Equity (ROE) improved to 12.1% from 8.6%, and ROCE rose to 19.1% from 15.5% YoY.
The Board recommended a final dividend of 15% (₹0.30 per share on a face value of ₹2).
👀 What to Watch
Investors should focus on the strong order book which provides over 2x revenue visibility for the coming years. The successful diversification into green hydrogen and sustainable fuels through the Chemdist JV adds a high-growth catalyst to the traditional business.
JNK India FY26 Net Profit Surges 115% to ₹648.7M; Recommends ₹0.30 Dividend
JNK India Limited reported a robust financial performance for the fiscal year ended March 31, 2026, with revenue from operations growing nearly 60% YoY to ₹7,556.11 million. The company's net profit more than doubled, reaching ₹648.71 million compared to ₹301.41 million in the previous year. Reflecting this strong growth, the board has recommended a final dividend of ₹0.30 per equity share. Additionally, the company expanded its footprint by investing in a new subsidiary, JNK Chemdist Technologies, during the year.
Key Highlights
Revenue from operations grew 59.6% YoY to ₹7,556.11 million in FY26.
Net profit for the year jumped 115.2% to ₹648.71 million from ₹301.41 million.
Recommended a final dividend of ₹0.30 per share (15% of face value of ₹2).
Basic Earnings Per Share (EPS) rose significantly to ₹11.59 from ₹5.46 in the previous year.
Total Comprehensive Income for the year stood at ₹651.66 million.
👀 What to Watch
Given the doubling of profits and strong revenue momentum, investors should view this as a positive growth indicator. The stock remains attractive for those seeking exposure to specialized engineering segments, though one should monitor the execution of the newly formed subsidiary.
JNK India FY26 Net Profit Jumps 115% to ₹648.7M; Recommends ₹0.30 Dividend
JNK India reported a stellar performance for FY26, with revenue from operations growing 60% year-on-year to ₹7,556.11 million. Net profit more than doubled, reaching ₹648.71 million compared to ₹301.41 million in the previous fiscal year. The board has recommended a final dividend of ₹0.30 per share, representing 15% of the face value. Additionally, the company expanded its operations by acquiring a 51% stake in a new subsidiary, JNK Chemdist Technologies, for ₹5.10 million.
Key Highlights
Revenue from operations surged 60% YoY to ₹7,556.11 million in FY26
Net profit for the full year increased by 115% to ₹648.71 million from ₹301.41 million
Board recommended a final dividend of ₹0.30 per equity share (15% of FV ₹2)
Basic EPS improved significantly to ₹11.59 in FY26 from ₹5.46 in FY25
Invested ₹5.10 million for a 51% stake in new subsidiary JNK Chemdist Technologies
👀 What to Watch
The strong growth trajectory in both top-line and bottom-line suggests robust execution and market demand; investors should maintain a positive outlook while monitoring the performance of the new subsidiary.
JNK India FY26 Standalone Net Profit Surges 115% to ₹648.7 Million; Dividend Declared
JNK India delivered a stellar performance for the financial year ended March 31, 2026, with standalone revenue from operations growing 59.6% YoY to ₹7,556.11 million. The company's net profit more than doubled, reaching ₹648.71 million compared to ₹301.41 million in the previous fiscal year. Shareholders are set to receive a final dividend of ₹0.30 per equity share (15% of face value). Additionally, the company expanded its operations by acquiring a 51% stake in JNK Chemdist Technologies Private Limited during the year.
Key Highlights
Standalone Revenue from Operations increased 59.6% YoY to ₹7,556.11 million in FY26.
Net Profit for the full year jumped 115% to ₹648.71 million from ₹301.41 million in FY25.
Board recommended a final dividend of ₹0.30 per equity share of face value ₹2.
Basic Earnings Per Share (EPS) rose significantly to ₹11.59 from ₹5.46 in the previous year.
Company invested ₹5.10 million to acquire a 51% ownership in JNK Chemdist Technologies Private Limited.
👀 What to Watch
The company demonstrates strong growth momentum and efficient execution in the specialized engineering space. Investors should maintain a positive outlook given the doubling of profits and consistent dividend payouts.
JNK India FY26 Net Profit Jumps 115% to ₹648.7M; Recommends ₹0.30 Dividend
JNK India reported a robust performance for the financial year ended March 31, 2026, with standalone revenue growing nearly 60% year-on-year to ₹7,556.11 million. Net profit for the full year more than doubled, reaching ₹648.71 million compared to ₹301.41 million in the previous fiscal. The Board has recommended a final dividend of ₹0.30 per share (15% of face value). Additionally, the company expanded its footprint by investing in a new subsidiary, JNK Chemdist Technologies, during the year.
Key Highlights
Annual Revenue from Operations surged 59.6% YoY to ₹7,556.11 million in FY26
Net Profit for FY26 increased by 115.2% to ₹648.71 million from ₹301.41 million in FY25
Q4 FY26 Net Profit stood at ₹316.63 million, a significant jump from ₹132.72 million in Q4 FY25
Board recommended a final dividend of ₹0.30 per equity share of face value ₹2
Company acquired a 51% stake in JNK Chemdist Technologies Private Limited during the fiscal year
👀 What to Watch
The strong growth trajectory in both top-line and bottom-line suggests high execution efficiency in the fired heaters segment. Investors should monitor the order book and the performance of the new subsidiary for sustained momentum.
Mankind Pharma Q4FY26: Adj. EBITDA Jumps 31% YoY, Revenue Up 11.8% to ₹3,443 Cr
Mankind Pharma reported a strong Q4FY26 with revenue growing 11.8% YoY to ₹3,443 crore, driven by a 13.4% increase in domestic sales. The company's adjusted EBITDA margin expanded significantly by 400 bps to 27.1%, resulting in a 31.1% YoY growth in adjusted EBITDA. While the full-year PAT saw a slight decline of 3.4% to ₹1,938 crore, the domestic chronic segment and OTC business showed robust growth of 14.7% (Cardiac) and 20% respectively. The acquisition of BSV continues to bolster the specialty portfolio, although international markets faced geopolitical headwinds.
Key Highlights
Q4FY26 Adjusted EBITDA rose 31.1% YoY to ₹933 crore with margins expanding 400 bps to 27.1%.
Domestic revenue grew 13.4% YoY to ₹2,886 crore, supported by a 14.7% growth in the Cardiac segment.
Consumer Healthcare (OTC) business grew 20% YoY in Q4, led by strong e-commerce performance.
Chronic share in the domestic business increased by 120 bps YoY to approximately 40%.
Full-year FY26 revenue reached ₹14,278 crore, marking a 17% YoY increase despite muted international growth.
👀 What to Watch
Investors should view the significant margin expansion and the increasing share of high-margin chronic therapies as positive indicators of long-term profitability. The successful integration of BSV and growth in the OTC segment further strengthen the company's domestic leadership.
Mankind Pharma Q4 FY26 Revenue Up 12% to ₹3,443 Cr; Adj. EBITDA Margin Expands to 27.1%
Mankind Pharma reported a strong Q4 FY26 with revenue growing 11.8% YoY to ₹3,443 crore and PAT rising 30.4% to ₹559 crore. The company's adjusted EBITDA margin expanded significantly by 400 bps to 27.1%, driven by a strategic shift towards chronic therapies and the integration of Bharat Serums and Vaccines (BSV). Domestic business remains the primary driver, growing 13.4% YoY, while the Consumer Healthcare segment saw robust 19.8% growth. Net debt to EBITDA has improved to 1.1x, demonstrating efficient deleveraging post-acquisition.
Key Highlights
Q4 FY26 Revenue grew 11.8% YoY to ₹3,443 Cr, while PAT surged 30.4% to ₹559 Cr.
Adjusted EBITDA margin improved by 400 bps YoY to 27.1% in Q4 FY26.
Chronic therapy share increased to 40%, with Cardiac and Anti-Diabetes segments growing at 14.7% and 11.6% respectively.
Consumer Healthcare segment revenue grew 19.8% YoY in Q4, with E-commerce share rising to 13%.
Net Debt/EBITDA ratio improved to 1.1x from 1.8x earlier in the year following the BSV acquisition.
👀 What to Watch
Investors should monitor the continued margin expansion and the increasing contribution of high-margin chronic and specialty segments. The successful integration of BSV and entry into Oncology and CNS segments provide strong catalysts for long-term growth.
Mankind Pharma FY26 Results: ₹500Cr Subsidiary Investment & Top Execs Waive Commission
Mankind Pharma reported its FY26 financial results alongside several strategic board decisions. The company approved an additional investment of up to ₹500 crores in its subsidiary, Mankind Medicare, to fuel expansion. In a significant move for fiscal discipline, the Executive Chairman, MD, and CEO have voluntarily waived their commissions for FY 2025-26 to strengthen the company's cash position. Additionally, the company announced the resignation of its Global CIO and the re-appointment of a Whole-Time Director for five years.
Key Highlights
Approved additional investment of up to ₹500 crores in wholly-owned subsidiary Mankind Medicare Private Limited.
Executive Chairman, MD, and CEO waived their FY25-26 commissions to preserve cash for business expansion.
Global CIO Pramod Gokhale resigned effective May 31, 2026; Satish Kumar Sharma re-appointed as WTD for 5 years.
Realignment of security cover for NCDs following the redemption of ₹1,250 crores on April 16, 2026.
Audited standalone and consolidated financial results for FY26 approved with an unmodified audit opinion.
👀 What to Watch
The voluntary commission waiver by top leadership is a strong positive signal of promoter alignment and commitment to growth. Investors should monitor the progress of the ₹500 crore investment in the Medicare subsidiary as a driver for future capacity.
Mankind Pharma to Invest ₹500 Cr in Subsidiary; Top Executives Waive FY26 Commission
Mankind Pharma's board has approved a significant additional investment of up to ₹500 crores in its wholly owned subsidiary, Mankind Medicare Private Limited, to fuel expansion. In a notable move to strengthen the company's cash position, the Executive Chairman, MD, and CEO have voluntarily waived their commissions for the 2025-26 financial year. The company also completed a ₹1,250 crore NCD redemption in April 2026, leading to a realignment of security covers. While the Global CIO has resigned, the board has secured leadership stability by re-appointing a Whole-Time Director for five years.
Key Highlights
Approved additional investment of up to ₹500 crores in Mankind Medicare Private Limited for business growth.
Executive Chairman, MD, and CEO waived their FY 2025-26 commissions to preserve cash for expansion.
Successfully redeemed ₹1,250 crores worth of Non-Convertible Debentures (NCDs) on April 16, 2026.
Re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for a 5-year term starting September 2026.
Global CIO Mr. Pramod Gokhale resigned effective May 31, 2026, as part of management changes.
👀 What to Watch
The voluntary waiver of commissions by top management is a strong positive signal of promoter alignment and fiscal prudence. Investors should view the ₹500 crore subsidiary investment as a commitment to long-term capacity building.
